Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent Mechanism

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Downregulation of DNA damage repair genes is a key area in cancer research, highlighted by the success of PARP inhibitors.
• Cyclin-dependent kinases 12 and 13 (CDK12/13) regulate RNA polymerase II and gene transcription, making them promising therapeutic targets for cancer.
• Existing CDK12/13 inhibitors often use covalent warheads, with limited clinical progression.

Purpose of the Study:

• To design and develop novel, highly selective, noncovalent inhibitors targeting CDK12 and CDK13.
• To identify a lead compound with potent activity and favorable drug-like properties for potential cancer therapy.

Main Methods:

• Structure-based drug design and medicinal chemistry approaches were employed.
• Development and optimization of a series of noncovalent small molecule inhibitors.
• Evaluation of compound potency, selectivity, and pharmacokinetic properties (ADME).

Main Results:

• A series of highly selective noncovalent inhibitors targeting CDK12 and CDK13 were successfully designed and synthesized.
• A lead compound was identified with outstanding potency against CDK12/13.
• The lead compound demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) profiles and good pharmacokinetic properties.

Conclusions:

• Noncovalent inhibition represents a viable strategy for targeting CDK12 and CDK13.
• The identified lead compound exhibits significant potential for therapeutic applications in cancer treatment.
• Further development of these inhibitors could offer new avenues for cancer therapy by exploiting synthetic lethality.